These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 33853817)

  • 1. Dysosmia and drug tolerance with use of venlafaxine.
    Rousseau C; Malaty J
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33853817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysosmia and dysgeusia associated with duloxetine.
    Yoshida K; Fukuchi T; Sugawara H
    BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29170185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine.
    Koga M; Kodaka F; Miyata H; Nakayama K
    Acta Psychiatr Scand; 2009 Oct; 120(4):329-31. PubMed ID: 19573048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venlafaxine induced QTc interval prolongation in a therapeutic dose.
    Bavle A
    Asian J Psychiatr; 2015 Aug; 16():63-4. PubMed ID: 26187237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
    Ye W; Zhao Y; Robinson RL; Swindle RW
    BMC Psychiatry; 2011 Jan; 11():19. PubMed ID: 21281479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.
    Fann JR; Bombardier CH; Richards JS; Wilson CS; Heinemann AW; Warren AM; Brooks L; McCullumsmith CB; Temkin NR; Warms C; Tate DG;
    JAMA Psychiatry; 2015 Mar; 72(3):247-58. PubMed ID: 25607727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
    Shelton RC; Haman KL; Rapaport MH; Kiev A; Smith WT; Hirschfeld RM; Lydiard RB; Zajecka JM; Dunner DL
    J Clin Psychiatry; 2006 Nov; 67(11):1674-81. PubMed ID: 17196045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter to the Editor: Depression As The First Symptom Of Frontal Lobe Grade 2 Malignant Glioma.
    Nazlı ŞB; Sevindik M
    Turk Psikiyatri Derg; 2022; 33(2):143-145. PubMed ID: 35730515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seizure Induced by a Therapeutic Dose of Venlafaxine ER: A Case Report.
    Ye C; Ninneman M; Christian JS; Zhang F; Musselman D
    J Psychiatr Pract; 2018 Mar; 24(2):117-120. PubMed ID: 29509182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.
    van Baardewijk M; Vis PM; Einarson TR
    Curr Med Res Opin; 2005 Aug; 21(8):1271-9. PubMed ID: 16083537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression.
    Johnson EM; Whyte E; Mulsant BH; Pollock BG; Weber E; Begley AE; Reynolds CF
    Am J Geriatr Psychiatry; 2006 Sep; 14(9):796-802. PubMed ID: 16943176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials.
    Vis PM; van Baardewijk M; Einarson TR
    Ann Pharmacother; 2005 Nov; 39(11):1798-807. PubMed ID: 16189284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension and orthostatic hypotension with venlafaxine treatment in depressed older adults.
    Wathra R; Mulsant BH; Thomson L; Goldberger KW; Lenze EJ; Karp JF; Sanches M; Reynolds CF; Blumberger DM
    J Psychopharmacol; 2020 Oct; 34(10):1112-1118. PubMed ID: 32842836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Ketamine Self-Injections in Major Depressive Disorder: Focus on Tolerance in Ketamine's Antidepressant Response and the Development of Ketamine Addiction.
    Bonnet U
    J Psychoactive Drugs; 2015; 47(4):276-85. PubMed ID: 26317449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Discontinuing venlafaxine by switching to fluoxetine].
    Bet PM; Köktaş IO; Bergh M
    Tijdschr Psychiatr; 2018; 60(11):782-785. PubMed ID: 30484571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder.
    Fernandez JL; Montgomery S; Francois C
    Pharmacoeconomics; 2005; 23(2):155-67. PubMed ID: 15748090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.